Al's Comment:

 Interesting trial about to open for DIPG.  This drug, OKN-007 recently reported good results for recurrent Glioblastoma, with an average survival of about 20 months compared to historical average of about 8 months. The Musella Foundation gave one of the first grants to get this started, back in 2013! I wish them luck and I will let you know when the trial opens.

Posted on: 12/10/2020

Oblato Announces Discussion Outcome with FDA for Development of OKN-007 for Diffuse Intrinsic Pontine Glioma


Click HERE to return to brain tumor news headlines.